ABT-199 Clinical Trials Suspended After Patient Death

Following a death due to tumor lysis syndrome, AbbVie has suspended the ABT-199 clinical trial program. ABT-199 is a promising new drug in development for chronic lymphocytic leukemia that was about to enter Phase III drug development by the company.
Biotech Strategy Blog